Meeting
2021 ASCO Annual Meeting
Response to immune checkpoint inhibition as monotherapy or in combination with chemotherapy in metastatic ROS1-rearranged lung cancers.
Authors
Noura J. Choudhury
Memorial Sloan Kettering Cancer Center, New York, NY
Noura J. Choudhury , Jaime Laurel Schneider , Tejas Patil , Viola Weijia Zhu , Debra A. Goldman , Soo-Ryum Yang , Christina Falcon , Andrew Do , Yunan Nie , Andrew J. Plodkowski , Jamie E. Chaft , Subba Digumarthy , Natasha Rekhtman , Maria E. Arcila , Alexia Iasonos , Sai-Hong Ignatius Ou , Jessica Jiyeong Lin , Alexander E. Drilon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9049)
DOI
10.1200/JCO.2021.39.15_suppl.9049
Abstract #
9049
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Real-world effectiveness of immune checkpoint inhibitors alone or in combination with chemotherapy in metastatic non–small cell lung cancer.
First Author: Lingzhi Hong
Poster
2020 ASCO Virtual Scientific Program
Outcomes in patients with advanced non-small cell lung cancer (aNSCLC) and high PD-L1 expression treated with immune checkpoint inhibitor monotherapy: An FDA-pooled analysis.
First Author: Sujay Yogesh Shah
Poster
2019 ASCO Annual Meeting
A plasma miRNA signature classifier identifies PD-L1 ≥ 50% NSCLC nonresponders to immune checkpoint inhibitors.
First Author: Claudia Proto
Poster
2024 ASCO Annual Meeting
PD-L1 expression in pulmonary sarcomatoid carcinoma and response to immunotherapy.
First Author: Lingzhi Hong